Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).


NDAQ:JAZZ - Post by User

Jazz Pharmaceuticals plc > Cannabinoid Pharma
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(231)
•••
Comment by alleyesonmeon Jun 04, 2024 12:00pm
48 Views
Post# 36071290

RE:Cannabinoid Pharma

RE:Cannabinoid Pharma According to Jazz’s filings, in October 2023, it settled with Padagis US LLC and granted Padagis a license to manufacture, market, and sell its generic version of Epidiolex on a date that depends on the occurrence of certain other events.....medipharm labs is in an undisclosed partnership on a ANDA for the epidiolex generic...president stated earlier in the year they are preparing for launch..I think pagadis is the partner ....medipharm has a drug establishment license, a FDA drug master file with the FDA for cannabidol, a successful FDA site audit, DEA import permits (the only Canadian Corp to achieve this) and a high capacity GMP facility....it's very interesting Jazz has approved this generic...they must have a licensing agreement or some other beneficial arrangement...https://www.greenmarketreport.com/judge-not-swayed-in-patent-battle-over-epidiolex-patents/.        https://stockhouse.com/news/press-releases/2023/08/01/medipharm-labs-makes-first-delivery-of-cannabis-clinical-trial-material-to-us
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities